PD-L2 can bind the immune checkpoint PD-1. However, its potential as a therapeutic target for immune checkpoint blockade in cancer has not been extensively explored. Here, the authors demonstrate that αPD-L2 is effective in aged, but not young, melanoma murine models.
- Carlos O. Ontiveros
- Myrna G. Garcia
- Tyler J. Curiel
